All In Biotech

Drug Trial Radar · NCT06279130

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

133

Planned (sponsor's estimate)

Start

Jan 29, 2024

Primary completion

Jan 29, 2029

Study completion Jan 29, 2034

Sponsor

Lead sponsor
The Netherlands Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Agenus Inc.
First posted
Feb 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, the efficacy of botensilimab and balstilimab in mismatch repair deficient (dMMR) and mismatch repair proficient (pMMR) tumors will be assessed.

Conditions

  • Resectable MMR-deficient Solid Tumors
  • Resectable MMR-proficient Solid Tumors

Interventions

  • botensilimabDrug

    Anti cytotoxic T-lymphocyte associated protein-4 (anti-CTLA4)

  • balstilimabDrug

    Anti programmed cell death protein-1 (anti-PD1)

  • FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)Drug

    5-Fluorouracil (2400mg/m2), leucovorin (200mg/m2), oxaliplatin (85mg/m2), docetaxel (50mg/m2).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major pathological response rateTime frame: Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Netherlands Cancer Institute

    Amsterdam, North Holland, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.